These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 33463756)

  • 1. Drug target validation in primary human natural killer cells using CRISPR RNP.
    Rautela J; Surgenor E; Huntington ND
    J Leukoc Biol; 2020 Oct; 108(4):1397-1408. PubMed ID: 33463756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ex Vivo Expansion and CRISPR-Cas9 Genome Editing of Primary Human Natural Killer Cells.
    Huang RS; Lai MC; Lin S
    Curr Protoc; 2021 Sep; 1(9):e246. PubMed ID: 34529358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity.
    Bernard PL; Delconte R; Pastor S; Laletin V; Costa Da Silva C; Goubard A; Josselin E; Castellano R; Krug A; Vernerey J; Devillier R; Olive D; Verhoeyen E; Vivier E; Huntington ND; Nunes J; Guittard G
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35589278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins.
    Naeimi Kararoudi M; Dolatshad H; Trikha P; Hussain SA; Elmas E; Foltz JA; Moseman JE; Thakkar A; Nakkula RJ; Lamb M; Chakravarti N; McLaughlin KJ; Lee DA
    J Vis Exp; 2018 Jun; (136):. PubMed ID: 29985369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR/Cas9-Based Gene Engineering of Human Natural Killer Cells: Protocols for Knockout and Readouts to Evaluate Their Efficacy.
    Lambert M; Leijonhufvud C; Segerberg F; Melenhorst JJ; Carlsten M
    Methods Mol Biol; 2020; 2121():213-239. PubMed ID: 32147798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization and validation of CAR transduction into human primary NK cells using CRISPR and AAV.
    Naeimi Kararoudi M; Likhite S; Elmas E; Yamamoto K; Schwartz M; Sorathia K; de Souza Fernandes Pereira M; Sezgin Y; Devine RD; Lyberger JM; Behbehani GK; Chakravarti N; Moriarity BS; Meyer K; Lee DA
    Cell Rep Methods; 2022 Jun; 2(6):100236. PubMed ID: 35784645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors.
    Oei VYS; Siernicka M; Graczyk-Jarzynka A; Hoel HJ; Yang W; Palacios D; Almåsbak H; Bajor M; Clement D; Brandt L; Önfelt B; Goodridge J; Winiarska M; Zagozdzon R; Olweus J; Kyte JA; Malmberg KJ
    Cancer Immunol Res; 2018 Apr; 6(4):467-480. PubMed ID: 29459477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation and validation of CRISPR-engineered human natural killer cell lines for research and therapeutic applications.
    Kumar A; Lee SJ; Liu Q; Chan AKN; Pokharel SP; Yu J; Chen CW; Swaminathan S
    STAR Protoc; 2021 Dec; 2(4):100874. PubMed ID: 34746857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy.
    Pomeroy EJ; Hunzeker JT; Kluesner MG; Lahr WS; Smeester BA; Crosby MR; Lonetree CL; Yamamoto K; Bendzick L; Miller JS; Geller MA; Walcheck B; Felices M; Webber BR; Starr TK; Moriarity BS
    Mol Ther; 2020 Jan; 28(1):52-63. PubMed ID: 31704085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ribonucleoprotein Transfection for CRISPR/Cas9-Mediated Gene Knockout in Primary T Cells.
    Oh SA; Seki A; Rutz S
    Curr Protoc Immunol; 2019 Feb; 124(1):e69. PubMed ID: 30334617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR-Cas9-Based Gene Knockout of Immune Checkpoints in Expanded NK Cells.
    Mohammadian Gol T; Kim M; Sinn R; Ureña-Bailén G; Stegmeyer S; Gratz PG; Zahedipour F; Roig-Merino A; Antony JS; Mezger M
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel non-viral delivery method that enables efficient engineering of primary human T cells for ex vivo cell therapy applications.
    Kavanagh H; Dunne S; Martin DS; McFadden E; Gallagher L; Schwaber J; Leonard S; O'Dea S
    Cytotherapy; 2021 Sep; 23(9):852-860. PubMed ID: 33941482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural Killer Cells Suppress T Cell-Associated Tumor Immune Evasion.
    Freeman AJ; Vervoort SJ; Ramsbottom KM; Kelly MJ; Michie J; Pijpers L; Johnstone RW; Kearney CJ; Oliaro J
    Cell Rep; 2019 Sep; 28(11):2784-2794.e5. PubMed ID: 31509742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients.
    Xiao L; Cen D; Gan H; Sun Y; Huang N; Xiong H; Jin Q; Su L; Liu X; Wang K; Yan G; Dong T; Wu S; Zhou P; Zhang J; Liang W; Ren J; Teng Y; Chen C; Xu XH
    Mol Ther; 2019 Jun; 27(6):1114-1125. PubMed ID: 30962163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies.
    Kloess S; Oberschmidt O; Dahlke J; Vu XK; Neudoerfl C; Kloos A; Gardlowski T; Matthies N; Heuser M; Meyer J; Sauer M; Falk C; Koehl U; Schambach A; Morgan MA
    Hum Gene Ther; 2019 Apr; 30(4):381-401. PubMed ID: 30734584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth.
    Oelsner S; Waldmann A; Billmeier A; Röder J; Lindner A; Ullrich E; Marschalek R; Dotti G; Jung G; Große-Hovest L; Oberoi P; Bader P; Wels WS
    Int J Cancer; 2019 Oct; 145(7):1935-1945. PubMed ID: 30860598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
    Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
    Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modification of Expanded NK Cells with Chimeric Antigen Receptor mRNA for Adoptive Cellular Therapy.
    Chu Y; Flower A; Cairo MS
    Methods Mol Biol; 2016; 1441():215-30. PubMed ID: 27177669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging.
    Daldrup-Link HE; Meier R; Rudelius M; Piontek G; Piert M; Metz S; Settles M; Uherek C; Wels W; Schlegel J; Rummeny EJ
    Eur Radiol; 2005 Jan; 15(1):4-13. PubMed ID: 15616814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells.
    Hu B; Zou Y; Zhang L; Tang J; Niedermann G; Firat E; Huang X; Zhu X
    Hum Gene Ther; 2019 Apr; 30(4):446-458. PubMed ID: 29706119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.